Introduction
Dierent chromosomal translocations fusing genes coding for tyrosine kinases and proteins bearing domains involved in dimerization result in haematological malignancies. The TEL/PDGFRb (T/P) is a chimeric oncogene formed by the chromosomal translocation t(5;12) that fuses the amino terminus of TEL to the transmembrane and cytoplasmic domains of the platelet-derived growth factor receptor b (PDGFRb) (Golub et al., 1994) . The self-association of T/P mediated by the helix ± loop ± helix (HLH) domain of TEL leads to constitutive activation of the PDGFRb tyrosine kinase and stimulation of PDGFRb-dependent signalling pathways (Carroll et al., 1996; Jousset et al., 1997) .
PDGF binding to its receptor induces dimerization, tyrosine kinase activation and autophosphorylation on several tyrosine residues which provide docking sites for a variety of proteins that mediate downstream signal transduction events (for review see Heldin, 1995) . Indeed, autophosphorylation of PDGFR leads to association of phospholipase Cg (PLCg), the 85 kDa subunit of phosphoinositide-3 OH kinase (PI-3 kinase), Src family members (Src, Fyn, Yes), Nck, RasGTPaseactivating protein (RasGAP), Syp and Shc which is known to mediate Ras stimulation via Grb2 and Sos (Yokote et al., 1994) . The pathways activated by Syp, PLCg and Shc, that converge to Ras activation as well as other pathways initiated by Nck, Src family tyrosine kinases and PI-3 kinase, are necessary for PDGFinduced cell growth (Ullrich and Schlessinger, 1991; Satoh et al., 1993) .
The mitogen-activated protein kinase (MAPK) cascades are highly conserved in all eukaryotes and participate in various intracellular signalling pathways that control a wide spectrum of cellular responses including cell growth, dierentiation and stress responses. Four groups of MAPKs have been identi®ed in mammalian cells; the extracellular signalregulated kinases (ERKs) (also referred to as p42/44 MAPK) (for review see Davis, 1993) , the c-Jun Nterminal kinases/stress-activated protein kinases (JNK/ SAPKs) (DeÂ rijard et al., 1994; Kallunki et al., 1994; Kyriakis et al., 1994) , p38/CSBP/RK/MPK2/MX12 (Han et al., 1994; Lee et al., 1995) , and ERK5 (Lee et al., 1997 ., Abe et al., 1996 . The mammalian ERKs are involved in growth factor-mediated activation and dierentiation of a variety of cells, and are activated by growth factors and mitogens such as epidermal growth factor (EGF), PDGF and insulin. Growth factor binding to receptor tyrosine kinases produces stimulation of a Ras-dependent kinase cascade that includes the sequential phosphorylation and activation of Raf, MAPK kinase 1 (MEK1), and ERKs. Once activated, ERKs translocate to the nucleus where they phosphorylate and activate the transcription factor ELK-1 (Whitmarsh and Davis, 1996; Gille et al., 1992) .
The JNK/SAPK pathway is activated in response to a wide variety of stimuli such as transforming growth factor-b (TGF-b) and several forms of environmental stress, including the in¯ammatory cytokines tumour necrosis factor a (TNFa) and Interleukin-1 (IL-1), osmotic shock, ultraviolet light, g radiation, and protein synthesis inhibitors (Fanger et al., 1997) . Like ERKs, the activated JNK/SAPKs translocate to the nucleus where they phosphorylate transcription factors such as c-Jun (DeÂ rijard et al., 1994) and ATF2 (Gupta et al., 1995; van Dam et al., 1995) . Furthermore, JNK/ SAPK activation requires phosphorylation at two residues, Thr-183 and Tyr-185 by the MAPK kinase 4 (MKK4, also called SEK1, MEK4 or JNKK/ SAPKK) Lin et al., 1995; Sanchez et al., 1994) , a dual speci®city protein kinase. MKK4 itself is phosphorylated by upstream MAPK kinase kinases such as MEKK1 (Yan et al., 1994) , apoptosis signal regulating kinase (ASK1) (Ichijo et al., 1997) or TGF-b-activated kinase 1 (TAK1) (Yamaguchi et al., 1995) . Experiments with a series of dominant-inhibitory or constitutively activated mutant proteins have indicated that the Rho family GTPases, Cdc42H and Rac initiate a cascade leading to JNK/SAPK (Coso et al., 1995; Minden et al., 1995) , presumably by binding and activating the protein kinase PAK, a kinase that phosphorylates and promotes activation of MEKK1.
The JNK/SAPK pathway has widely been studied in the context of stress activation. Although a relationship between a variety of stimuli that induce apoptosis and/ or growth arrest and JNK/SAPK activation has been established, several growth promoting and survival factors such as EGF (Bost et al., 1997) , PDGF (Xie and Herschman, 1996) , and IL-3 (Nagata et al., 1997; Terada et al., 1997) have been shown to activate JNK/ SAPK pathway in dierent cell lines. Interestingly, certain cellular oncogenes such as Met (Rodrigues et al., 1997) and BCR/ABL (Raitano et al., 1995) can also stimulate JNK/SAPK signalling pathway, which leads to cellular transformation. However, the signalling pathways through which these growth factors and oncogenes activate JNK/SAPK pathway are still unde®ned. Recently, it has been reported that a dominant negative form of PI-3 kinase as well as PI-3 kinase inhibitors block EGF-induced JNK/SAPK activation, although these inhibitors had no eect on JNK/SAPK activation induced by UV irradiation, osmotic shock, or TNFa (Logan et al., 1997) . Furthermore, both PI-3 kinase and JNK/SAPK pathway activation has been shown to be involved in the transforming potential of the human leukaemia oncogene, BCR/ABL (Skorski et al., 1997; Raitano et al., 1995) . Because T/P is also associated with haematological malignancies and more precisely with chronic myelomonocytic leukaemia (CMML), we investigated the possible role of JNK/SAPK cascade in transformation of the murine haematopoietic cell line Ba/F3 which requires interleukin-3 (IL-3) for growth and survival.
Here we report that T/P initiates a cascade leading to JNK/SAPK activation. Expression of dominant interfering mutants of various components of JNK/ SAPK cascade including MKK4 or TAK1 blocks T/Pmediated JNK/SAPK activation. In contrast, the inhibition of PI-3 kinase pathway enhances JNK/ SAPK activation by T/P, an eect that correlates with the induction of programmed cell death or apoptosis. Furthermore, we found that expression of the dominant negative mutant of MKK4 suppresses the apoptosis that occurs spontaneously in cells expressing the oncogenic T/P. Taken together, these data indicate that activation of JNK/SAPK pathway by TEL/PDGFRb is related to apoptosis rather than proliferation and transformation.
Results
T/P activates JNK/SAPK activity in Ba/F3 cells Expression of T/P leads to IL-3 independence for growth of Ba/F3 cells (Carroll et al., 1996; and this study) . One of the mechanisms by which the T/P fusion protein can transform haematopoietic cells may also be to prevent apoptotic cell death in response to IL-3 deprivation. To investigate the mechanism underlying the transformation by T/P, we sought to identify the signal transduction pathways that are activated by this fusion protein in the bone marrow-derived Ba/F3 cells. The transcription factor c-Jun has attracted recent interest as its activation might be a promoting factor for apoptotic cell death but can also be involved in proliferative and transformation responses. To determine whether the expression of c-Jun was aected by T/P, we determined the c-Jun levels in Ba/F3 cells stably transfected with an expression vector encoding T/P (Ba/F3.T/P) or an empty expression vector. Western blot analysis of protein extracts from cells transfected with T/P or with the control vector indicated that in the presence of IL-3 a high level of c-Jun was observed. However, when the cells were cultured for 18 h in the absence of the cytokine, c-Jun Figure 1 c-Jun expression and JNK activity in control and T/Ptransfected Ba/F3 cells. (a) whole cell extracts from control and T/P-expressing Ba/F3 cells were separated by SDS ± PAGE and immunoblotting of c-Jun was performed using anti-c-Jun polyclonal antibodies. (b) Cell lysates were immunoprecipitated with anti-JNK/SAPK1 antibody and JNK/SAPK activity was determined in immunoprecipitates by kinase assay using GST-Jun (1 ± 79) as substrate. The phosphoproteins were resolved by SDS ± PAGE and visualized by autoradiography. (c) Anti-JNK/SAPK immunoblotting of whole cell extracts showed that similar amount of JNK/SAPK1 proteins was recovered in each sample. Results are representative of at least three independent experiments levels dramatically decreased in control cells, whereas they remained high in the T/P transfected cells, suggesting that T/P expression was sucient to induce c-Jun expression ( Figure 1a ). It is also important to note that the increase in c-Jun expression by T/P was associated with a shift in c-Jun migration on SDS ± PAGE, as evidence by the appearance of a c-Jun species with markedly reduced mobility. A similar shift in migration was observed in c-Jun isolated from Ba/ F3 cells treated with the survival factor IL-3.
To identify the signalling pathway through which T/ P acts to increase c-Jun expression, we took advantage of the previous ®nding that c-Jun phosphorylated by JNK/SAPK on both Ser-63 and Ser-73 undergoes a shift in mobility on SDS ± PAGE (Lee et al., 1997) . To test the possibility that T/P triggers JNK/SAPK activation, protein extracts from control or T/Ptransfected cells were immunoprecipitated with an anti JNK/SAPK1 antibody and JNK/SAPK1 activity was determined in vitro using GST-jun as substrate. As shown in Figure 1b , T/P-expressing cells had constitutive activation of endogenous JNK/SAPK1, which is approximately four times higher than the one observed in untransfected Ba/F3 cells cultured without IL-3. As previously described (Terada et al., 1997) , this cytokine induces JNK/SAPK activity in Ba/F3 cells and when T/P-expressing cells were cultured in the presence of IL-3, the eect on JNK/SAPK activity was additive, suggesting that T/P and IL-3 are not acting on the same pathway to activate JNK/SAPK. JNK/SAPK1 expression estimated by Western blotting was unchanged by IL-3 treatment or by T/P expression ( Figure 1c) .
In an analogous approach to assess the ability of T/ P to activate JNK/SAPK1, we have transiently coexpressed an haemagglutinin (HA) epitope-tagged JNK/SAPK1 expression plasmid together with an expression vector encoding T/P and assayed JNK/ SAPK kinase activity in immunoprecipitates using an anti-HA antibody. Consistent with previous results, expression of T/P caused a strong increase in HA-JNK/SAPK1 activity, indicating that this eect is not a general phenomenon due to cellular transformation ( Figure 3a) . It is now established that SAPK/JNKs are responsible for phosphorylating the transactivating domain of c-Jun protein in vivo, and, in turn, phosphorylated c-Jun homodimers have potent AP-1 activity and can control the expression of a number of genes, including c-jun itself. This observation makes very likely that, T/P induces c-Jun expression through activation of JNK/SAPKs.
T/P induced JNK/SAPK activation requires the tyrosine kinase activity of PDGFRb
It has been established that the tyrosine kinase activity of T/P was involved in the transforming capacity of this fusion protein (Carroll et al., 1996; Jousset et al., 1997) . To determine whether the kinase activity of T/P is required for JNK/SAPK activation, we made the use of the protein kinase inhibitor (CGP53716) which is speci®c for PDGFR tyrosine kinase (Buchdunger et al., 1995) and completely inhibits the T/P-associated tyrosine kinase activity without modifying the overall pattern of tyrosine phosphorylation . Similarly, treatment of T/P-expressing Ba/F3 cells with CGP53716 completely inhibits JNK/SAPK activation ( Figure 2 ). This eect is likely to be speci®c, because CGP53716 is unable to inhibit JNK/SAPK activation mediated by IL-3 in Ba/F3 cells. Here again, eects of IL-3 and T/P on JNK/SAPK activation were cumulative and in T/P-expressing cells treated with IL-3, CGP53716 inhibited only T/P-induced JNK/SAPK activation, which is consistent with the notion that T/P and IL-3 trigger distinct signalling pathways to activate JNK/SAPK (data not shown).
Eect of expression of dominant negative mutants of various components of the JNK/SAPK cascade on T/P-induced JNK/SAPK activation
Recently, Rac1 and Cdc42H have been shown to function in the regulation of kinase cascades leading to activation of the JNK/SAPK Coso et al., 1995) . If Rho-like GTPases mediate signalling from T/P to JNK/SAPK, then dominant negative versions of these G proteins might be expected to abrogate T/P-induced JNK/SAPK activation. To test this possibility, Ba/F3 cells were transiently cotransfected with T/P together with HA-JNK/SAPK1 and either N17Rac1, N17Cdc42H, or N19RhoA. As shown in Figure 3a , expression of N17Rac1, N17Cdc42H or N19RhoA had no eect on JNK/SAPK activation by T/P. Since transfection eciency is low in Ba/F3 cells (around 10%), we could not detect an overexpression of these proteins compared to the endogenous ones. Nevertheless, these vectors have been used by us and others as dominantnegative mutants with respect to JNK activation by several environmental stimuli Coso et al., 1995) . As a control, expression of a dominantinterfering mutant of MKK4 (MKK4 Ala), the kinase that phosphorylates and promotes activation of JNK/ SAPK, blocked the majority of T/P-induced activation of JNK/SAPK. In contrast, expression of a dominantinterfering mutant of MEKK1 (MEKK1 K432A), a downstream component of the Rac and Cdc42H in the biochemical route to JNK/SAPK, failed to inhibit the activation of JNK/SAPK by T/P, which is consistent with the hypothesis that Rho-like GTPases are not required for T/P-mediated JNK/SAPK activation. Figure 2 The tyrosine kinase activity is required for T/P-induced JNK/SAPK activity. Ba/F3-TP or control cells were treated for 16 h with 0.3 mM CGP53716 in the presence or in the absence of IL-3. Cell lysates were immunoprecipitated with anti JNK antibody and assayed for JNK activity as described in Figure  1b . Results showed are representative of at least three independent experiments
In addition to MEKK1, other kinases have been proposed to function as MAPK kinase kinases including TAK1 (Yamaguchi et al., 1995) and ASK1 (Ichijo et al., 1997) . To further dissect the mechanism of activation of JNK/SAPK activation by T/P, we determined the ability of dominant-interfering mutants of TAK1 (TAK1 K63W) and ASK1 (ASK1 KR) to suppress HA-JNK/SAPK activation by T/P. As shown in Figure 3b , expression of a dominant negative mutant of TAK1 inhibited T/Pinduced JNK/SAPK activation, whereas expression of a dominant negative mutant of ASK1 had no eect. These results, together with the previous ®ndings that TAK1 promotes the phosphorylation and activation of MKK4 (Yamaguchi et al., 1995) , strongly suggest that TAK1 is the major mediator of JNK/SAPK activation by T/P. This observation was particularly intriguing since previous studies indicated that overexpression of a constitutively activated form of TAK1 triggers apoptotic cell death (Shibuya et al., 1998) .
Lack of involvement of PI-3 kinase in JNK/SAPK activation by T/P Like expression of T/P, expression of the fusion protein BCR/ABL leads to malignant transformation of haematopoietic cells. This eect seems likely to involve activation of JNK/SAPK cascade since overexpression of a dominant-interfering mutant of c-Jun suppressed BCR/Abl-induced cellular transformation (Raitano et al., 1995) . Furthermore, PI-3 kinase has also been implicated in cellular transformation by BCR/ABL (Skorski et al., 1997) . If PI-3 kinase lies downstream of T/P to JNK/SAPK, one would expect that PI-3 kinase activity would mirror JNK/SAPK activity. However, clearly the opposite is true, as treatment of T/Pexpressing cells by the irreversible inhibitor of PI-3 kinase, LY294002, potentiated the stimulatory eect of T/P on JNK/SAPK activity (Figure 4a) .
During the course of this study, we noticed that the oncogenic T/P can elicit both pro-and anti-apoptotic pathways, with the latter pathway being dominant in Figure 3 Eect of dominant negative mutants of JNK/SAPK pathway on T/P-induced JNK/SAPK activation. (a) Ba/F3 cells were transfected with 2 mg of T/P or the same amount of the control vector and 2 mg of pc-DNA3-HA-JNK/SAPK1 together with the indicated expression vectors or empty vectors (1 mg per transfection in each case). Cells were incubated for 16 h in the absence of IL-3 and cell extracts were assayed for JNK activity using the HA monoclonal antibody 12CA5. Part of the immunoprecipitation was resolved by SDS ± PAGE, transferred on nitrocellulose and immunoblotted with an anti-HA polyclonal antibody to assess that the same amount of HA-JNK/SAPK1 was used to determinate JNK activity. (b) Ba/F3 cells were transfected with 2 mg of T/P or the same amount of the control vector and 2 mg of pc-DNA3-HA-JNK/SAPK1 together with the indicated expression vectors or empty vectors (1 mg per transfection in each case) and cell extracts were processed as in (a) the haematopoietic Ba/F3 cells (our unpublished observation). Furthermore, recent studies indicate that PI-3 kinase is a general mediator of growth factorinduced survival and has been shown to suppress the apoptotic death of a number of cell types induced by a variety of stimuli, including growth factor withdrawal, loss of cell adhesion, and cellular transformation (Songyang et al., 1997; Alessi and Cohen, 1998) . These observations, together with the ®ndings that inhibition of PI-3 kinase activity potentiated the stimulatory eect of T/P on JNK/SAPK activity (Figure 4a ), prompted us to determine the potential role of JNK/SAPK and PI-3 kinase in T/P-mediated cell death. To address this question, T/P-expressing cells were treated with LY294002 and the extent of apoptosis was determined by measuring DNA laddering characteristic of cell death. It is important to note that the sensitivity of this technique is insucient to detect cell death occurring spontaneously in T/Pexpressing cells. Figure 4b demonstrated that DNA extracted from untreated T/P-expressing cells did not show any DNA laddering, whereas typical oligonucleosomal DNA laddering was evident from LY294002-treated cells expressing T/P. These data are consistent with the hypothesis that JNK/SAPK cascade plays a role in T/P-mediated cell death.
Expression of a dominant negative mutant of MKK4 inhibits apoptosis in T/P-expressing Ba/F3 cells
To obtain direct evidence that T/P-induced JNK/ SAPK activation leads to apoptosis, T/P-expressing Ba/F3 cells were transfected with a dominant negative mutant of MKK4 (MKK4 Ala) together with a plasmid encoding the green¯uorescent protein (GFP) to allow for the identi®cation of transfected cells. As previously established, transfected cells eectively expressed both GFP and the cotransfected plasmid, and the stability of GFP during apoptosis allowed identi®cation of dying cells (BesancË on et al., 1998) . To quantitate the results in a blinded manner, we scored, after DAPI staining, the number of apoptotic cells in the population of transfected cells based upon nuclear morphology. We have previously shown that around 17% of the Ba/F3.T/P cells were apoptotic compared to around 8% in the Ba/F3 cells maintained in the presence of IL-3 (BesancË on et al., 1998). We here observed that over 15% of green cells arising from transfection with GFP alone were apoptotic, while less than 5% of cells that had been transfected with MKK4 Ala showed morphological changes consistent with apoptosis ( Figure 5) . Thus, expression of MKK4 Ala provided protective eect against T/P-mediated cell death. Consistent with this interpretation, we obtained identical results with the dominant-interfering mutant of TAK1, the expression of which was also eective in suppressing T/P-mediated JNK activation (data not shown). Under these experimental conditions, expression of the dominant-negative mutant of PI-3 kinase induces a threefold increase in apoptosis relative to cells expressing T/P and empty vector ( Figure 5 ). From these data, it is becoming evident the JNK/SAPK pathway acts downstream of T/P to generate apoptotic cell death. 
Discussion
The T/P fusion protein can transform haematopoietic cells presumably by preventing apoptotic cell death in response to IL-3 deprivation. Unexpectedly, we show that T/P can be also an eective inducer of apoptosis, suggesting that this fusion protein activates contradictory intracellular pathways that can modulate cell viability. This result is comparable to what was observed for Ras where Ras-mediated activation of the Raf pathway promotes apoptosis in ®broblasts whereas Ras-mediated activation of the PI-3 kinase pathway suppresses it (Kaumann-Zeh et al., 1997). In the case of T/P, induction of apoptosis correlated with the ability of T/P to increase the expression of c-Jun through JNK/SAPK signalling pathways. Consistent with this observation, overexpression of a dominantinterfering mutant of TAK1, a potent inducer of apoptotic cell death (Shibuya et al., 1998) , blocked the majority of T/P-mediated JNK/SAPK activation. Furthermore, inhibition of PI-3 kinase activity by LY294002 potentiated the eect of T/P on JNK/SAPK activity, which is associated with extensive cell death. Direct evidence that activation of JNK/SAPK pathways are required for cell death mediated by T/P in Ba/ F3 cells comes from the observation that the dominantnegative mutant of MKK4 is capable of impairing JNK/SAPK activation and cell death induced by T/P.
Our data are consistent with a model in which the JNK/SAPK cascade participates in the proapoptotic pathway activated by T/P. How T/P couples to the JNK/SAPK signalling pathway is still unclear. Recently, Rac and Cdc42H have been shown to activate JNK/SAPK signalling pathway leading to cJun transcriptional activation. However, overexpression of dominant-interfering mutants of these Rho-like GTPases had no eect on T/P-mediated JNK/SAPK activation. Noteworthy, several studies indicated that activation of the JNK/SAPK cascade through Rho-like GTPases is an essential component of several oncogene-induced malignant transformation and that it may play a role in development of metastasis. The identi®cation of downstream events that connect T/P to JNK/SAPK signalling pathway should provide insights into the mechanism by which T/P promotes cell survival and cellular transformation.
The pivotal role of the JNK/SAPK cascade in cell survival as well as cell transformation is very complex. On the one hand, recent studies have revealed that activation of the JNK/SAPK cascade is an essential component of malignant transformation induced by the BCR/ABL fusion protein (Raitano et al., 1995) as well as several oncogenes such as Met or Src (Rodrigues et al., 1997; Minden et al., 1995) . On the other hand, several groups have also reported that activation of the JNK/SAPK pathway can also induce cell death. For example, activation of JNK/SAPK in the absence of ERK activity induces apoptosis in neural cells (Xia et al., 1995) . Furthermore, expression of MEKK1, an upstream activator of JNK/SAPK results in the apoptotic death of ®broblasts , suggesting that under some circumstances, JNK/SAPK signalling alone may be sucient to cause cell death. In other studies, it has been shown that activation of ASK1, a kinase of the JNK/SAPK pathway that functions in response to TNFa is sucient to induce apoptosis and is required for TNFa-induced cell death (Ichijo et al., 1997) . From all these studies, it is becoming clear that the regulation of programmed cell death is a very complex phenomenon which varies both with the cell type and the inducer of apoptosis. In any event, our data demonstrate that T/P can elicit both antiapoptotic and proapoptotic pathways and that JNK/SAPK cascade participates in the apoptotic pathway.
It has been reported that PDGFR activates JNK/ SAPK through the PI-3 kinase pathway (LopezIlasacca et al., 1997) , whereas this pathway is not implicated in JNK/SAPK activation induced by TNFa, UV irradiation or osmotic shock (Logan et al., 1997) . In our studies, PI-3 kinase seems to be a negative regulator of JNK/SAPK activation by T/P since the PI-3 kinase inhibitor LY294002 does not inhibit T/Pinduced JNK/SAPK activation, but on the contrary, potentiates this activation and increased apoptosis. Moreover, JNK/SAPK is not activated in Ba/F3 cells stably expressing a constitutively activated mutant of PI-3 kinase, and are unable to undergo cell death following survival factor withdrawal (unpublished data). The discrepancy between our result and the activation of JNK/SAPK by PDGF through PI-3 kinase activation may be due to dierent cellular localization of PDGFR and T/P since it has been shown that the T/P fusion protein is located in the cytoplasm (Jousset et al., 1997) , whereas PDGFR is a transmembrane protein. Moreover, in the case of JNK/ SAPK activation by PDGF, the experiments have been performed in CHO cells and it has been reported that the pathways activated by PDGF to induce DNA synthesis in CHO and Ba/F3 cells are dierent since PDGFRb mutants which are not capable to induce DNA synthesis in CHO cells after PDGF stimulation are able to do so in Ba/F3 cells (Satoh et al., 1993) . Other studies have demonstrated that in ®broblasts, although PDGF is a potent activator of PI-3 kinase, it does not stimulate the JNK/SAPK signalling pathway.
The PI-3 kinase inhibitor LY294002 totally inhibited cell growth of T/P-expressing Ba/F3 cells (not shown) suggesting that PI-3 kinase activation could be a downstream eector of T/P in the biochemical route to cell proliferation and transformation. An example of this scenario is the cellular transformation of haematopoietic cells by the fusion protein BCR-ABL which occurs via PI-3 kinase/AKT signalling pathways (Skorski et al., 1997) . Other alternative mechanisms might also exist as our previous studies indicated that the activity of the c-myc protooncogene is essential for the transforming capacity of T/P . This T/P-induced c-myc expression also plays a role in an antiapoptotic pathway via the activation of the transcriptional factor NF-kB (BesancË on et al., 1998). These observations raise the interesting possibility that T/P fusion protein, through phosphorylation of its tyrosine residues triggers a plethora of potential biological outcomes, some of which, like JNK/SAPK cascade may be contradictory with the oncogenic potential of this fusion protein. Therefore, the proapoptotic activity of T/P may limit the expansion and malignant progression of cells bearing this chromosomal translocation. In accordance with this hypothesis, T/P expression leads to chronic myelomonocytic leukaemia (CMML), a myelodysplasic syn-drome which corresponds to a transition between normal haematopoiesis and leukaemia. It would be of interest to study JNK/SAPK activation during transition of this CMML to leukaemia.
Materials and methods

Vectors
Full length TEL/PDGFRb cDNA inserted into the pSRa/ MSV/TK/neo retroviral expressing vector was described previously (Golub et al., 1994) . The dominant-interfering mutants pcDNA3-FLAG-MKK4 Ala, pCEV29N19RhoA, pCEV29N17Rac1, pCEV29N17Cdc42H, and pCMV5-MEKK (K432A) have also been described . Expression plasmid for dominant-interfering mutant of TAK1 (pEF-TAK1 K63W) was a gift from Dr H Shibuya. Expression plasmid for dominant-interfering mutant of ASK1 (pCDNA3-ASK1 KR) was kindly provided by Dr H Ichijo. GST-Jun and pcDNA3-HA-JNK1 have been described . The expression plasmid encoding the dominantinterfering mutant of PI-3 kinase (p110 Dkin) was a gift from Dr Klippel. The pEGFP vector encoding for GFP was from CLONTECH. GST-Jun (1 ± 79) was expressed in Escherichia coli as described .
Cell culture and transfections
The murine bone marrow-derived IL-3-dependent Ba/F3 cells were maintained in RPMI containing 10% foetal calf serum and 5% WEHI 3B cell-conditioned medium as a source of IL-3. For experiments, 1 ng/ml of murine recombinant IL-3 (proTech Rocky Hill NJ, USA.) was used instead of WEHI supernatant. To remove IL-3, cells were washed twice in RPMI 10% calf serum. Cells were transfected with the dierent vectors by electroporation at 0.24 Kv, 960 mF using a BioRad apparatus. Selection of stable transfectants has been already described . Stability of the transfectants was routinely tested by determining the expression of T/P protein by Western blot analysis using antiPDGFRb antibodies.
Western blot analysis
Cells were lysed in 20 mM Tris pH 6.7, 0.5% SDS, boiled 3 min and treated with 1 unit of Benzon nuclease for 10 min at room temperature. Total cell lysates were subjected to SDS ± PAGE and electrophoretically transferred into nitrocellulose ®lters (at 50 mA for 15 h in 20 mM Tris, 150 mM glycine, 20% (v/v) ethanol and 0.2% SDS). Western blotting was performed with anti c-Jun or anti-JNK/SAPK antibodies (Santa-Cruz Laboratories). Blots were revealed with sheep anti-mouse or anti-rabbit IgG horseradish peroxidase-linked antibodies and chemiluminescence (ECL Amersham).
Protein kinase assay
JNK/SAPK kinase activity was determined as described with minor modi®cations. Brie¯y, cells were lysed in a buer containing 10 mM Tris (pH 7.4), 150 mM NaC1, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 0.5% NP40, 0.5 mM sodium vanadate, 0.2 mM PMSF and 10% glycerol. Lysates were clari®ed by centrifugation and endogenous JNK/SAPK1 was immunoprecipitated with the polyclonal anti JNK/SAPK1 antibody. Immune complexes were collected by binding to protein G-Sepharose, washed three times in lysis buer and resuspended in 30 ml of kinase reaction mixture containing 12.5 mM MOPS (pH 7.5), 12.5 mM b-glycerophosphate, 7.5 mM MgC1 2 , 0.5 mM EGTA, 0.5 mM sodium¯uoride, 0.5 mM sodium vanadate, 2 mg of GST-Jun, 20 mM unlabelled ATP and 5 mCig 32 ATP. After incubation at 208C for 30 min, kinase reaction products were analysed by SDS ± PAGE and autoradiographed. The HA epitope-tagged JNK/SAPK1 activity was also determined by immunocomplex kinase assays after immunoprecipitation with the HA monoclonal antibody 12CA5.
Apoptosis assays
Ba/F3 cells expressing T/P were transiently transfected with expression vectors encoding for MKK4 Ala or p110 Dkin together with the GFP expression vector. To detect DNA fragmentation in situ, cells were ®xed with 4% paraformaldehyde for 20 min, washed with PBS, and stained with DAPI (2 mg/ml). Cells were observed under¯uorescent microscope.
For analysis of DNA fragmentation, 2610 6 cells were collected by centrifugation and lysed with 30 ml of buer containing 20 mM Tris-HC1 (pH 7.5), 10 mM EDTA, and 0.5% Triton X-100. Cell extracts were clari®ed by centrifugation at 10 000 g for 5 min and the lysates were incubated with proteinase K (0.2 mg/ml) and ribonuclease A (0.1 mg/ ml) at 428C for 1 h. DNA was electrophoresed in 0.5 6 TBE running buer (4.5 mM Tris, 4.5 mM boric acid, 62.5 mM EDTA) on a 2% agarose gel containing ethidium bromide.
